Supernus Pharmaceuticals (SUPN) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Supernus Pharmaceuticals (SUPN) is Neutral.

The composite score behind that read is -0.06, weighing +0.11 of bullish evidence against -0.32 bearish.

Supernus Pharmaceuticals last closed at $42.67, +1.26% on the session.

Against the IVW growth benchmark the position is +0.46% over the forecast window.

The read is built from 15 underlying insights — 5 bullish and 10 bearish.

Agreement across those insights is 67%.

20 graded predictions for SUPN so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Supernus Pharmaceuticals in the 32nd percentile on return on equity, where 100 is best.

Supernus Pharmaceuticals is classified under Health Care / Pharmaceuticals, with a market capitalisation of $2.45B.

StockMap tracks Supernus Pharmaceuticals as the 35th largest of the 151 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.

Across that group the current two-week reads are 90 Neutral, 46 Moderate Underperform and 15 Moderate Outperform.

On that composite Supernus Pharmaceuticals ranks 73rd of 151 in the group, against a group median of -0.08.